Results 151 to 160 of about 754,759 (237)

Approaches of dengue control: vaccine strategies and future aspects

Frontiers in Immunology
Dengue, caused by the dengue virus (DENV), affects millions of people worldwide every year. This virus has two distinct life cycles, one in the human and another in the mosquito, and both cycles are crucial to be controlled. To control the vector of DENV,
Runa Akter, Runa Akter, Faria Tasneem, Shuvo Das, Mahfuza Afroz Soma, Ilias Georgakopoulos-Soares, Rifat Tasnim Juthi, Saiful Arefeen Sazed   +7 more
doaj   +1 more source

Dengue and Dengue Vaccines [PDF]

The Journal of Infectious Diseases, 2005
openaire   +1 more source

Progress in dengue vaccine research: a review

Zhongguo gonggong weisheng
Databases such as ClinicalTrials, PubMed, and China National Knowledge Infrastructure (CNKI) were used to search for studies on the research progress of different dengue vaccine development strategies in ongoing or completed global clinical trials ...
Guanting ZHANG, Jieling WANG, Ruipeng LU, Hui DENG, Mingji CHENG, Shengjun HU, Jinhua DUAN   +6 more
doaj   +1 more source

Development of novel vaccines for the concurrent immunisation against multiple dengue virus serotypes

, 2006
A major obstacle to the development of dengue virus (DENV) vaccines has been the need to immunise concurrently against each of the four DENV serotypes in order to avoid sensitising recipients to developing severe DENV infections.
Liew, Steven Christopher
core  

Assessing the potential of a candidate dengue vaccine with mathematical modeling [PDF]

, 2012
Dengue viruses are single-stranded positive-sense RNA viruses (genus Flavivirus, family Flaviviridae) that are the etiological agents of dengue fever (DF).
WHO-VMI Dengue Vaccine Modeling Group, Gomes, M. Gabriela M.   +1 more
core  

The dengue vaccine dilemma [PDF]

The Lancet Infectious Diseases, 2018
openaire   +2 more sources

State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature

Background: Dengue virus infection is a significant challenge for global health, with 100 million symptomatic cases, 2.3 million DALYs and 20,000 deaths annually.
Anna Barbiero, Paolo Bonanni, Davide Marangoni, Alessandro Bartoloni, Michele Spinicci, Lorenzo Zammarchi, Andrea Rossanese   +6 more
core   +1 more source

Dengue vaccines

, 2013
Scott B. Halstead, Stephen J. Thomas
openaire   +1 more source

Challenges and Opportunities in the Development of Dengue Vaccines: A Comprehensive Review. [PDF]

Adv Biomed Res
Moghadasi R, Yadollahi Fars Y, Nasri H, Momenzadeh M.   +3 more
europepmc   +1 more source

From promise to pitfalls: immunological lessons from dengue vaccines and their implications. [PDF]

NPJ Vaccines
Estofolete CF, Saivish MV, Nogueira ML, Vasilakis N.   +3 more
europepmc   +1 more source